Skip to main content
TipRanks
Go Ultimate75% OFF

Oramed Pharm (ORMP) AI Stock Analysis

535 Followers
ORMP

Oramed Pharm

(NASDAQ:ORMP)

Select Model
Rating:46Neutral
Price Target:$4.00â–²(7.82% Upside)
Action:reiterated
Date:11/13/26

The overall score of 46 reflects a high-risk, pre-revenue biotechnology company. The primary strength is a robust balance sheet that provides a financial buffer, but this is heavily offset by the complete lack of operational revenue, persistent cash burn, and weak technical price trends. The anomalous P/E ratio is not considered a positive factor due to its non-operational nature.

Positive Factors
Low leverage and strong capitalizationVery low debt relative to equity gives Oramed meaningful financial flexibility and reduces near-term solvency pressure. This capitalization can help fund clinical development and absorb operating losses, although its lasting value depends on converting resources into sustainable business performance.
Negative Factors
Minimal commercial revenueThe absence of a meaningful recurring revenue base shows that Oramed has not yet established a durable commercial engine. This leaves future funding capacity dependent on existing resources, financing, partnerships, or successful product development rather than internally generated operating revenue.

Oramed Pharm (ORMP) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%125%150%ORMP+59.84%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$154.33M
Dividend Yield
―
Average Volume (3M)
172.48K
Price to Earnings (P/E)
1.1
Beta (1Y)
0.48
Revenue Growth
-100.00%
EPS Growth
238.88%
Country
US
Employees
13
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Oramed Pharm Business Overview & Revenue Model

Company Description

Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypep...

Oramed Pharm Financial Statement Overview

Summary

Financial performance is highly polarized. The balance sheet is a fortress with minimal debt and substantial equity, providing a long cash runway. However, the income statement shows zero revenue and a core business that is not self-sustaining, while cash flow is consistently negative. The overall financial health is entirely dependent on existing reserves.

Income Statement

35Negative

Balance Sheet

75Positive

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Sep 2023Dec 2022Aug 2021
Income Statement
Total Revenue02.00M01.34M2.70M2.70M
Gross Profit-91.00K13.00K01.34M2.70M2.70M
EBITDA151.83M75.44M-14.87M7.32M-40.54M-24.15M
Net Income174.87M64.05M-19.06M5.53M-37.76M-22.24M
Balance Sheet
Total Assets369.64M230.86M155.28M220.55M161.64M128.00M
Cash, Cash Equivalents and Short-Term Investments50.61M125.89M141.93M162.05M155.72M94.14M
Total Debt733.00K825.00K372.00K51.62M894.00K533.00K
Total Liabilities52.17M31.12M9.93M57.66M10.49M11.48M
Stockholders Equity317.47M199.74M146.26M163.82M151.81M115.77M
Cash Flow
Free Cash Flow-5.01M-11.08M-8.43M-10.55M-29.20M-21.56M
Operating Cash Flow-5.21M-9.14M-8.41M-10.29M-28.70M-21.18M
Investing Cash Flow21.50M5.44M105.82M-73.04M30.21M-22.26M
Financing Cash Flow-16.68M-4.74M-52.04M51.98M11.56M101.39M

Oramed Pharm Technical Analysis

Technical Analysis SentimentNegative
Last Price3.71

Price Trends

50DMA4.36Negative
100DMA4.41Negative
200DMA4.06Negative

Market Momentum

MACD-0.12Positive
RSI34.41Neutral
STOCH40.72Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORMP, the sentiment is Negative. The current price of 3.71 is below the 20-day moving average (MA) of 4.05, below the 50-day MA of 4.36, and below the 200-day MA of 4.06, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 34.41 is Neutral, neither overbought nor oversold. The STOCH value of 40.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ORMP.

Oramed Pharm Risk Analysis

Oramed Pharm disclosed 42 risk factors in its most recent earnings report. Oramed Pharm reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.We may have difficulty realizing the full value of the Warrants.Q4, 2023
2.We have lent a substantial amount of funds to Scilex. In the event that Scilex is unable to service its obligations under the Note and defaults on such Note, it could have a material adverse effect on our business.Q4, 2023
3.If we fail to complete the transactions contemplated under the JV Agreement with HTIT, if such joint venture is not successful, or if we fail to realize the benefits we anticipate from such joint venture, we may not be able to capitalize on the full market potential of our drug products and technology.Q4, 2023

Oramed Pharm Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ORMP against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SPRBSPRB47Neutral$123.27M-1.24-118.22%―-100.00%58.95%
ORMPORMP46Neutral$167.64M1.0652.95%―-100.00%238.88%
ALXOALXO42Neutral$149.34M-0.92-90.30%――48.20%
WHWKWHWK40Underperform$181.16M-2.81-55.66%―-100.00%-825.52%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%ORMPWHWKALXOSPRBDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ORMP and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ORMPOramed Pharmaceuticals Inc3.711.5370.11%
WHWKWhitehawk Therapeutics, Inc.3.060.9444.34%
ALXOAlx Oncology Holdings, Inc.1.04-0.52-33.33%
SPRBSpruce Biosciences, Inc.43.31-65.53-60.21%

Oramed Pharm Corporate Events

Business Operations and StrategyExecutive/Board ChangesShareholder Meetings

Oramed Pharm Shareholders Back Governance and Incentive Plan

Positive
Sep 17, 2026

At its Annual Meeting of Stockholders held on September 15, 2026, Oramed Pharm shareholders re-elected all incumbent directors to serve until the next annual meeting and ratified the appointment of Kesselman & Kesselman, a member of PricewaterhouseCo...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026